Covidien Expects Continued Growth In Neurovascular Division

With more than $30 million invested in stroke clinical trials and technology, Covidien sees tremendous opportunity in the endovascular treatment of acute ischemic stroke. The company’s ongoing research is laying the foundation for continued growth in its neurovascular division.

The endovascular device market for acute ischemic stroke (AIS) is facing several challenges that could slow market growth, including negative clinical trial results, threats to reimbursement, increasing regulatory requirements, and a challenging funding environment. (See Also see "Stroke Devices: Hope Amid Headwinds" - Medtech Insight, 27 September, 2013..) Despite these headwinds, market leader Medtronic Minimally Invasive Therapies sees opportunity ahead and believes AIS treatments will play a significant role in the future growth of its neurovascular division. According to Brett Wall, president of Covidien’s neurovascular division, who spoke recently with Medtech Insight, there are a number of clinical trials ongoing with Covidien’s Solitaire line of neurothrombectomy devices, and the firm has a strong commitment to the neurointerventional space.

In January 2013 Covidien began enrolling patients in the Solitaire FR as Primary Treatment for Acute Ischemic Stroke (SWIFT PRIME)...

More from Archive

More from In Vivo